San Diego-based Zogenix has called off the firm's IPO, according to a filing with the SEC by the company late Friday. According to Zogenix, it is withdrawing its IPO, which it had originally filed for in March, due to "general market conditions." Zogenix had been looking to raise up to $86.25M on the Nasdaq Global Market. The firm's IPO had been underwritten by Banc of America Securities, Leerink Swann, Thomas Weisel Partners, and Susquehanna Financial Group. Zogenix is backed by Domain Associates, Clarus Lifesciences, Scale Venture Partners, Thomas McNerney & Partners, Abingworth Bioventures, and others; the firm's products are used for treatment of pain and central nervous system disorders.